Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning vs evening dosing of sacubitril/valsartan for hypertension
ChiCTR2100054606Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sacubitril + valsartan in essential hypertension (3 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Blood pressure. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2100054606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054606.